{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:36:49Z","timestamp":1783445809726,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772848"],"award-info":[{"award-number":["81772848"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572452"],"award-info":[{"award-number":["81572452"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703225"],"award-info":[{"award-number":["81703225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Funds for the Innovation of Science and Technology from Fujian Province","award":["2017Y9127"],"award-info":[{"award-number":["2017Y9127"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2016J01577"],"award-info":[{"award-number":["2016J01577"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1160-9","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T13:03:47Z","timestamp":1554728627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Valproic acid exhibits anti-tumor activity selectively against EGFR\/ErbB2\/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs"],"prefix":"10.1186","volume":"38","author":[{"given":"Tingting","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1160_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605\u201317.","journal-title":"N Engl J Med"},{"key":"1160_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","volume":"363","author":"D Li","year":"2004","unstructured":"Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049\u201357.","journal-title":"Lancet."},{"key":"1160_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177\u201393.","journal-title":"CA Cancer J Clin"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nrc949","volume":"2","author":"N Bardeesy","year":"2002","unstructured":"Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897\u2013909.","journal-title":"Nat Rev Cancer"},{"key":"1160_CR6","doi-asserted-by":"publisher","first-page":"18913","DOI":"10.1073\/pnas.0810097105","volume":"105","author":"N Habbe","year":"2008","unstructured":"Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A. 2008;105:18913\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1160_CR7","doi-asserted-by":"publisher","first-page":"18907","DOI":"10.1073\/pnas.0810111105","volume":"105","author":"OJ La De","year":"2008","unstructured":"De La OJ, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2008;105:18907\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1160_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc.2016.66","volume":"16","author":"A Makohon-Moore","year":"2016","unstructured":"Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553\u201365.","journal-title":"Nat Rev Cancer"},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3322\/caac.21190","volume":"63","author":"CL Wolfgang","year":"2013","unstructured":"Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318\u201348.","journal-title":"CA Cancer J Clin"},{"key":"1160_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.","journal-title":"Nature."},{"key":"1160_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399\u2013405.","journal-title":"Nature."},{"key":"1160_CR12","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-12-1215","volume":"18","author":"S Yachida","year":"2012","unstructured":"Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012;18:6339\u201347.","journal-title":"Clin Cancer Res"},{"key":"1160_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761\u201374.","journal-title":"Nat Rev Cancer"},{"key":"1160_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117\u201334.","journal-title":"Cell."},{"key":"1160_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282\u2013303.","journal-title":"Cancer Cell"},{"key":"1160_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00000658-199912000-00005","volume":"230","author":"H Friess","year":"1999","unstructured":"Friess H, Wang L, Zhu Z, Gerber R, Schroder M, Fukuda A, et al. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg. 1999;230:767\u201374.","journal-title":"Ann Surg"},{"key":"1160_CR17","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.18632\/oncotarget.2231","volume":"5","author":"G Thomas","year":"2014","unstructured":"Thomas G, Chardes T, Gaborit N, Mollevi C, Leconet W, Robert B, et al. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014;5:7138\u201348.","journal-title":"Oncotarget."},{"key":"1160_CR18","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-06-2302","volume":"13","author":"C Larbouret","year":"2007","unstructured":"Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res. 2007;13:3356\u201362.","journal-title":"Clin Cancer Res"},{"key":"1160_CR19","doi-asserted-by":"publisher","first-page":"15389","DOI":"10.1073\/pnas.1313857110","volume":"110","author":"R Maron","year":"2013","unstructured":"Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M. Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2\/ErbB-2. Proc Natl Acad Sci U S A. 2013;110:15389\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1160_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2016.05.037","volume":"379","author":"J Gore","year":"2016","unstructured":"Gore J, Imasuen-Williams IE, Conteh AM, Craven KE, Cheng M, Korc M. Combined targeting of TGF-\u03b2, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer Lett. 2016;379:143\u201353.","journal-title":"Cancer Lett"},{"key":"1160_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"1160_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"1160_CR23","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1158\/0008-5472.CAN-09-2146","volume":"69","author":"X Huang","year":"2009","unstructured":"Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009;69:8403\u201311.","journal-title":"Cancer Res"},{"key":"1160_CR24","doi-asserted-by":"publisher","first-page":"e556","DOI":"10.1038\/cddis.2013.79","volume":"4","author":"S Wang","year":"2013","unstructured":"Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2\/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013;4:e556.","journal-title":"Cell Death Dis"},{"key":"1160_CR25","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-11-0767","volume":"18","author":"OA Botrugno","year":"2012","unstructured":"Botrugno OA, Robert T, Vanoli F, Foiani M, Minucci S. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy. Clin Cancer Res. 2012;18:2436\u201342.","journal-title":"Clin Cancer Res"},{"key":"1160_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.canlet.2010.04.014","volume":"296","author":"CK Lee","year":"2010","unstructured":"Lee CK, Wang S, Huang X, Ryder J, Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010;296:233\u201340.","journal-title":"Cancer Lett"},{"key":"1160_CR27","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1038\/onc.2010.180","volume":"29","author":"S Wang","year":"2010","unstructured":"Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene. 2010;29:4225\u201336.","journal-title":"Oncogene."},{"key":"1160_CR28","doi-asserted-by":"crossref","first-page":"37693","DOI":"10.18632\/oncotarget.9264","volume":"7","author":"S Wang","year":"2016","unstructured":"Wang S, Zhu L, Zuo W, Zeng Z, Huang L, Lin F, et al. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget. 2016;7:37693\u2013713.","journal-title":"Oncotarget."},{"key":"1160_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.0307708100","volume":"101","author":"CY Gui","year":"2004","unstructured":"Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A. 2004;101:1241\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1160_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell."},{"key":"1160_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58\u201371.","journal-title":"Cancer Cell"},{"key":"1160_CR32","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1073\/pnas.1018001108","volume":"109","author":"A Chakrabarty","year":"2012","unstructured":"Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A. 2012;109:2718\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1160_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0014-4827(02)00101-5","volume":"284","author":"A Citri","year":"2003","unstructured":"Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284:54\u201365.","journal-title":"Exp Cell Res"},{"key":"1160_CR34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.4161\/cbt.6.4.3849","volume":"6","author":"A Frolov","year":"2007","unstructured":"Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther. 2007;6:548\u201354.","journal-title":"Cancer Biol Ther"},{"key":"1160_CR35","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1002\/jcb.25988","volume":"118","author":"W Wei","year":"2017","unstructured":"Wei W, Liu Y, Lu Y, Yang B, Tang L. LncRNA XIST promotes pancreatic Cancer proliferation through miR-133a\/EGFR. J Cell Biochem. 2017;118:3349\u201358.","journal-title":"J Cell Biochem"},{"key":"1160_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13046-018-0813-4","volume":"37","author":"Y Tang","year":"2018","unstructured":"Tang Y, Pan J, Huang S, Peng X, Zou X, Luo Y, et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K\/AKT signaling. J Exp Clin Cancer Res. 2018;37:160.","journal-title":"J Exp Clin Cancer Res"},{"key":"1160_CR37","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1111\/j.1742-4658.2012.08741.x","volume":"279","author":"L Liu","year":"2012","unstructured":"Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang R, et al. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 2012;279:3800\u201312.","journal-title":"FEBS J"},{"key":"1160_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505\u201316.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1160_CR39","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","volume":"29","author":"CH Crane","year":"2011","unstructured":"Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29:3037\u201343.","journal-title":"J Clin Oncol"},{"key":"1160_CR40","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic Cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960\u20136.","journal-title":"J Clin Oncol"},{"key":"1160_CR41","doi-asserted-by":"crossref","first-page":"21085","DOI":"10.18632\/oncotarget.3912","volume":"6","author":"I Lakshmanan","year":"2015","unstructured":"Lakshmanan I, Seshacharyulu P, Haridas D, Rachagani S, Gupta S, Joshi S, et al. Novel HER3\/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget. 2015;6:21085\u201399.","journal-title":"Oncotarget."},{"key":"1160_CR42","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","volume":"8","author":"C Heining","year":"2018","unstructured":"Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, et al. NRG1 fusions in KRAS wild-type pancreatic Cancer. Cancer Discov. 2018;8:1087\u201395.","journal-title":"Cancer Discov"},{"key":"1160_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.canlet.2018.06.023","volume":"432","author":"C Ogier","year":"2018","unstructured":"Ogier C, Colombo PE, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, et al. Targeting the NRG1\/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett. 2018;432:227\u201336.","journal-title":"Cancer Lett"},{"key":"1160_CR44","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-05-0194","volume":"4","author":"DC Marchion","year":"2005","unstructured":"Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005;4:1993\u20132000.","journal-title":"Mol Cancer Ther"},{"key":"1160_CR45","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4161\/cbt.8.9.8118","volume":"8","author":"E Gennaro Di","year":"2009","unstructured":"Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther. 2009;8:782\u201391.","journal-title":"Cancer Biol Ther."},{"key":"1160_CR46","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/sj.bjc.6605969","volume":"103","author":"E Gennaro Di","year":"2010","unstructured":"Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, et al. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer. 2010;103:1680\u201391.","journal-title":"Br J Cancer"},{"key":"1160_CR47","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.18632\/oncotarget.6802","volume":"7","author":"M Terranova-Barberio","year":"2016","unstructured":"Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2016;7:7715\u201331.","journal-title":"Oncotarget."},{"key":"1160_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13046-017-0647-5","volume":"36","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, et al. Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. J Exp Clin Cancer Res. 2017;36:177.","journal-title":"J Exp Clin Cancer Res"},{"key":"1160_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13402-017-0314-z","volume":"40","author":"MS Gilardini Montani","year":"2017","unstructured":"Gilardini Montani MS, Granato M, Santoni C, Del Porto P, Merendino N, D'Orazi G, et al. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol (Dordr). 2017;40:167\u201380.","journal-title":"Cell Oncol (Dordr)"},{"key":"1160_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13046-018-0978-x","volume":"37","author":"M Noce La","year":"2018","unstructured":"La Noce M, Paino F, Mele L, Papaccio G, Regad T, Lombardi A, et al. HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. J Exp Clin Cancer Res. 2018;37:296.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1160-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1160-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1160-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T18:36:05Z","timestamp":1607193365000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1160-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1160-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Affiliated Dongfang Hospital of Xiamen University School of Medicine. Experiments with animals were performed in accordance to the guidelines for experimental animal managements established by Xiamen University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"150"}}